Calcification is a frequent cause of the clinical failure of bioprosthetic heart valves fabricated from glutaraldehyde-pretreated porcine aortic valves or glutaraldehyde-pretreated bovine pericardium (GPBP). We investigated the hypothesis that ferric chloride (FeCI,) and sodiumethanehydroxydiphosphonate (EHDP) may act synergistically to prevent bioprosthetic tissue calcification.
0.1 M) (1.78 f 0.2pg of Ca*+/mg of dried tissue) compared with the other pre-incubation groups: EHDP (first preincubation) combined with FeCI, (second pre-incubation) (21.7 k 6.4) FeCI, solution alone at 10m5 M (27.9 + 10.7), Na2EHDP solution alone at 0.1 M (52.3 + 11.9) and the control group (72.3 + 10.2) . In a second series of implants, G.PBP specimens were co-implanted with individual controlled release systems containing one of the following formulations (weight percentage in silicone rubber): 1% FeCI,, 20% CaEHDP, 20% protamine sulphate, 1% FeCI,-20% CaEHDP, and 1% FeCI,-20% protamine sulphate. The 1% FeC13-20% CaEHDP silicone-rubber matrices were the most effective for inhibiting GPBP mineralization (13.7 t 3.0,ag Ca*+/mg of dried tissue) compared with non-drug silicone co-implant controls (74.7 f 5.56 pg Ca*+/mg of dried tissue) and other polymeric treatment groups . No adverse effects on bone or overall growth of any treatment protocols were noted. Thus, combinations of FeC13 and EHDP, using either pre-incubations or polymeric controlled release, were synergistic for inhibiting GPBP calcification.
Keywords: Heart valves, calcification, pericardium, pre-incubation, controlled (Na,EHDP) controlled release matrices were co-implanted subdermally with GPBP tissue, and also inhibited calcification'3. However, this same drug used in pre-incubation studies with GPBP did not prevent the mineralization in rat subdermal implants14; this lack of efficacy was most likely due to a diffusion of EHDP out of GPBP tissue.
The goals of the present study were to assess the possible synergistic effect of diphosphonates and metallic salts on inhibiting bioprosthetic tissue mineralization. Therefore, the effects of FeCl, combined with EHDP (either by successive GPBP pre-incubations or co-incorporation in silicone-rubber matrices) were investigated on GPBP calcification in rat subdermal implant experiments. Pericardium from mature bovines was obtained fresh at slaughter, and was cross-linked as previously described4' lo in a 0.8% glutaraldehyde (diluted from an 8% aqueous solution, Polyscience, Warrington, PA, USA) solution buffered with 50 mM HEPES at pH 7.4, then transferred after 24 h to a 0.2% glutaraldehyde solution in the same buffer for storage at 4°C for 1 wk.
MATERIALS AND METHODS

Materials
Methods
In vitro pre-incubations GPBP specimens (1 cm') were rinsed free of glutaraldehyde with sterile saline and successively pre-incubated at 37°C in the FeCl, solution (1O-5 M, pH 3 for 24 h), then in the Na214C-EH.DP (0.1 M, pH 7.4 for 24 h), or vice versa. Control specimens of GPBP were pre-incubated in 50 mM HEPES buffer, pH 7.4 for 24 h at 37%. Afterward, the samples of pre-incubated GPBP were withdrawn, washed with distilled water and lyophilized. Half of the specimens were dissolved in tissue solubilizer (Solvable, DuPont, Boston, MA, USA) at 55-60°C and the Na,14C-EHDP was measured.
The other specimens were minced, hydrolysed in 6 N HCl as previously described4' lo, and the Fe3+ levels were determined by atomic absorption spectroscopy15.
Controlled release polymer formulation and in vitro release studies
All the agents (wt%/matrix) were incorporated as a matrix dispersion in Silastic Q-74840 prepolymer.
The silicone-rubber formulations containing the cocipients were prepared by levigating the A and B components of Silastic Q-74840 thoroughly with the drug, followed by compression moulding and curing at 250°C for l-2 h using a hydraulic press (70.2 X lo5 Pa).
The in vitro release of agents from slab materials (1 cm'] was conducted at 37°C using either an excess of 50 mM HEPES buffer pH 7.4 or K,HPO, buffer (pH 7.4). At each time point, 1 ml samples were withdrawn and the drug release was estimated. The Fe3+ content was measured chemically by atomic absorption spectroscopy'5. The Na,EHDP content was determined by measuring the released radioactivity of NaZf4C-EHDP with a liquid scintillation counter (Model LS 3801, Beckman, USA), and the PS release was analysed by using Lowry protein assayX6.
Implant and retrieval methods
Male weanling rats (50-60 g, CD, Sprague-Dawley, Charles River Laboratories, Burlington, MA, USA) were anaesthetized by an intramuscular injection of Ketamine and Rompun. Six subdermal pouches were dissected as previously described4* *' on each rat (four ventral, two dorsal) and GPBP specimens
(1 cm'), washed with distilled water to remove residual glutaraldehyde, were implanted in these pouches, either as isolated GPBP implants or as co-implants with polymeric matrices (1 cm', approximately 100 mg), with or without drugs, linked by surgical staples. The rats (two per group) were killed by CO, asphyxiation after 21 d. Explanted GPBP were washed with saline and distilled water, lyophilized and hydrolysed in 6 N HCl, as previously described, for calcium analysis by atomic absorption spectroscopy4, lo. 
Morphological analysis
RESULTS
Maximum uptake of Fe3+ and EHDP, and Fe3+ dissociation from GPBP tissues
The results presented
in 'Rbk f demonstrate that the sequence of pre-incubation had a significant effect on the Fe3+ and Na,EHDP content of the GPBP tissues. Initial pre-incubations of GPBP tissues in the FeCl, solution, followed by the Na,EHDP solution, resulted in Na,EHDP uptake an order of magnitude greater than the reverse sequence of pre-incubation.
The Fe3+ release from the successive pre-incubations by GPBP tissues are shown in Figure 1 . Both conditions studied demonstrated their most rapid elution rates during the first 24 h. After this time, a slower nearly constant release rate of Fe3 was noted to be roughly equal in both types of specimens. The Fe3" release rate from the GPBP tissues pre-incubated initially in the FeC& solution, then in the Na,EHDP solution, was almost twice as rapid during the first 24 h as for the GPBP tissues preincubated in the reverse order.
In vitro releases of EHDP and Fe3+ from the polymeric matrices
The results of in vitro release studies of the polymeric depicted in Figure 2 . Relatively slow sustained release of Fe3+ was noted with both types of matrices. After 21 d, the Fe3+ release from the polymeric matrix containing 1% FeCl,-20% CaEHDP (5%) was almost three times that of the 1% FeCl,-20% PS (2%).
In tivo studies
The calcium levels of 21 d subdermal implantations of GPBP tissues pre-incubated in either FeCl, or Na,EHDP solutions, or FeCl, combined with Na,EHDP are presented in ZWe 3. Pre-incubation in Na,EHDP (0.1 M) did not significantly inhibit the calcification (52.3 f 11.9 ,ug Ca'+/mg dried tissue) while FeCl, (lo-' M) pre-incubation partially inhibited the calcium accumulation (27.9 + 10.7 pg Ca'+/mg dried tissue] compared with the control group (72.3 + 10.2 pg Ca'+/mg dried tissue]. The greatest inhibition ,was observed when the GPBP tissue was first pre-incubated in FeCl, (lo-' M for 24 h) and then in Na,EHDP (0.1 M for another 24 h) (1.8 + 0.2 ,ug Ca'+/mg dried tissue). The reverse order of pre-incubation inhibited calcification less effectively than the previous group (21.7 I!Z 6.4j.ig Ca'+/mg dried tissue). The later calcium level was similar to the FeCl,-only pre-incubation group (7Me 1).
Co-implantation results of the FeCl,-CaEHDP controlled release systems with GPBP tissues are presented in Figure  3 . 
DISCUSSION
The present study demonstrated that FeCl, and EHDP acted synergistically to inhibit bioprosthetic tissue calcification in the rat subdermal model (21 d), whether administered by GPBP pre-incubation or controlled release co-implants. The prevention of GPBP calcification was significantly reduced in both types of inhibition studies: pre-incubations of GPBP tissues in successive FeCl, (lo-' M) and then Na,EHDP (0.1 M) solutions: and the FeCl, (l%)-CaEHDP (20%) controlled release system. The FeCl,-Na,EHDP pre-incubation synergism results point out the importance of the pre-incubation sequence. The optimal incubation order, FeCl, followed by Na,EHDP, allowed a higher uptake of both drugs, FeCl, and Na,EHDP, into the GPBP tissue. The reasons for the importance of the sequence of pre-incubation are not clear. Diphosphonates and water molecules may have formed complexes, as previously described", and therefore the Fe3+ ions are probably less easily incorporated into the tissue in the presence of these complexes. GPBP phosphates, which then readily adsorb EHDP, due to ionic attraction. Prior work by our group has in fact used electron energy-loss spectroscopy to demonstrate colocalization of A13+ (as an AlCl, pre-incubation) to GPBP phosphorus sites in cell membranes. Initial incubation with EHDP may block the metal-phosphorus interaction, leading to lower metal ion and EHDP uptake.
Controlled release of Na,EHDP has been demonstrated to be effective for inhibiting calcification in the rat subdermal modeV3, lg. ", while the GPBP pre-incubation in Na,EHDP did not inhibit calcification'4. Our data (Figure 3) show that 21% CaEHDP alone loaded into silicone-rubber matrices did not significantly inhibit GPBP mineralization compared with the control. The calcium salt of EHDP is 1000 times less soluble than the sodium salt14, so less drug will be released from CaEHDP matrices. Furthermore, other related work involving coimplantation of Fe3+ (10% loaded) or A13+ (1 or 10% loaded) controlled release systems with GPBP tissue in the rat subdermal implants (21 d) demonstrated anticalcification efficacy7. In this study, Fe3+ was loaded at a lower percentage (1%) than the previous studies just cited, so the Fe3+ release profile (Figure 2 ) also showed significantly slower release rates compared with earlier results7. Nevertheless, efficacy was evidently due to EHDP synergism.
PS is an inhibitor of GPBP calcification, but only when covalently bound to the tissue"; its mechanism is hypothesized to be due to charge modification. A previous paper by our group also reported the failure of controlled release PS for calcification inhibition using 10% loading PS in Q-74840 matrices7. Therefore, the controlled release PS used in the present study may be viewed as a control cocipient, since our earlier results demonstrated no effective inhibition of GPBP calcification using PS controlled release matrix co-implants.
Pre-incubations of bioprosthetic tissue in trivalent metallic salts such as FeCl, or AlCl, prevented GPBP implant calcification'* ' in rat subdermal studies. At the same time, explant AP activity was reduced due to FeCl, or AlCl, pre- 
